Self-amplifying RNA (saRNA) has many structural similarities to conventional mRNA: it is a linear, single-stranded RNA molecule that is synthesized with a 5' cap, 3' polyA tail, and 5' and 3' untranslated regions (UTRs). The main structural difference is that saRNA is a much larger molecule as it encodes four extra proteins in addition to the protein of interest or vaccine antigen. SaRNAs derived from the genomes of positive-strand RNA viruses have recently come into focus as a promising technology platform for vaccine development. Non-virally delivered self-amplifying mRNA vaccines have the potential to be highly versatile, potent, streamlined, scalable, and inexpensive. By amplifying their genome and the antigen encoding mRNA in the host cell, the self-amplifying mRNA mimics a viral infection, resulting in sustained levels of the target protein combined with self-adjuvanting innate immune responses, ultimately leading to potent and long-lasting antigen-specific humoral and cellular immune responses.

Benefits of self-amplifying RNA

• saRNA vaccines vaccines have the potential to be highly versatile and inexpensive.
• Manufacturing is cell-free, does not require a dedicated facility.
• saRNA vaccines perform high potent and long-lasting antigen-specific humoral and cellular immune responses.

IntegrateRNA offers a series of premade self-amplifying RNA products to satisfy your various downstream applications. You can easily measure the reporter gene expression in vivo/vitro to evaluate self-amplifying RNA and optimize delivery formulations of saRNA vaccine.